Management Team & Board of Directors

Ms. Moller joined MIMEDX in August 2020 as Senior Vice President, Sales and was appointed Chief Commercial Officer in June 2024. She brings significant sales leadership experience, clinical knowledge and understanding of the Advanced Wound Care marketplace to her role. With more than 25 years of experience in sales roles with increasing responsibility, Ms. Moller has managed national sales teams and executed on strategic growth initiatives for leading healthcare companies, including 3M and its subsidiaries Acelity and KCI.

Ms. Moller holds a B.S. in Nursing (BSN) from University of Phoenix and an MBA from Colorado Christian University.

Dr. Harper joined MIMEDX as Chief Technology Officer and Senior Vice President of Research and Product Development in June 2021. Most recently, he served as a Senior Medical Scientist in the Medical Solutions Division of 3M Health Care and Chief Technology Officer for 3M affiliate KCI, where he was responsible for all early-stage research, innovation and technology development and the study of mechanism of action of the company’s negative pressure wound care technology. During his tenure at KCI, Dr. Harper also led the company’s Clinical Development and Regulatory Affairs organization.  Prior to KCI, he served as Vice President of Clinical Development and Clinical Sciences at the biotechnology company LifeCell Corporation, the previous Regenerative Medicine division of Acelity and the leader in acellular scaffold technology and makers of AlloDerm, Strattice, and GraftJacket Regenerative and Reconstructive Tissue Matrices.

Dr. Harper has over 40 peer-reviewed publications and book chapters and his principal areas of research interest are extracellular matrix biochemistry, tissue regeneration, and wound healing.  He currently serves as a member of the Board of Directors at Kent Imaging, Nanomedic Technologies, and American College of Wound Healing and Tissue Repair.

He received his Ph.D. in Biomedical Sciences from The University of Texas, M.D. Anderson Cancer Center in Houston and completed post-doctoral fellowships in cancer biochemistry and cell biology at Scripps Clinic in La Jolla, California and the National Cancer Institute in Bethesda, Maryland.

Ms. Chastain joined MIMEDX in November 2025 as its Chief Human Resources Officer (CHRO). With more than 20 years of experience leading HR across healthcare, life sciences, and technology, she brings deep expertise in organizational design, talent strategy, and culture transformation.

Before joining MIMEDX, Ms. Chastain served as Senior Vice President of Human Resources at SCP Health, where she led HR operations for more than 7,500 providers across 400 healthcare facilities. Her work focused on building high-performing teams, streamlining HR processes, and strengthening organizational culture at scale. Earlier in her career, she was Senior Vice President of HR and Marketing at McKesson Specialty Health, overseeing HR strategy for a $24 billion business and 15,000 employees. Her leadership in transformation and talent management helped align people initiatives with business growth goals, fostering a culture of collaboration and excellence.

Ms. Chastain earned a Bachelor of Applied Sciences (B.A.Sc.) in Psychology from Georgia State University and an MBA from the Stetson School of Business and Economics at Mercer University.

Mr. Smith joined MIMEDX in 2021 and currently serves as the Senior Vice President of Marketing & International. Prior to MIMEDX, he was the Chief Commercial Officer at Ascensus Surgical (formerly known as TransEnterix), a global provider of abdominal robotics and augmented reality systems. Prior thereto, he was the Vice President and Global Acute Franchise Leader at Acelity (formerly known as KCI) responsible for all wound care products sold in the hospital setting. Mr. Smith has over 25 years’ experience in the health care sector and has had executive level roles in Johnson & Johnson, Boston Scientific and Signet Laboratories.

Mr. Smith holds a bachelor of science in business administration from the University of New Hampshire and a masters in business administration from Babson College.

Dr. M. Kathleen Behrens served as a member of the board of directors of each of Sarepta Therapeutics, Inc. (SRPT), a multi-billion dollar medical research and drug development company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, since March 2009 (Chairwoman of the Board since April 2015) and IGM Biosciences, Inc., from January 2019 until July 2025.

Dr. Behrens has worked as an independent life sciences consultant and investor since December 2009. She served as the Co-Founder, President, Chief Executive Officer and as a director of the KEW Group Inc., a private oncology services company, from January 2012 until June 2014.

Earlier in her career, Dr. Behrens served as a general partner for selected venture funds for RS Investments, a mutual fund firm, from 1996 until December 2009. While Dr. Behrens worked at RS Investments, from 1996 to 2002, she served as a managing director at the firm and, from 2003 to December 2009, she served as a consultant to the firm. During that time, Dr. Behrens also served as a member of the President’s Council of Advisors on Science and Technology (PCAST), from 2001 to 2009 and as chairwoman of PCAST’s Subcommittee on Personalized Medicine, as well as the President, director and chairwoman of the National Venture Capital Association, an organization that advocates for public policy that supports the American Entrepreneurial ecosystem, from 1993 until 2000. Prior to that, she served as a general partner and managing director for Robertson Stephens & Co., an investment company, from 1983 through 1996.

She served as a director of Amylin Pharmaceuticals, Inc. (formerly AMLN), a biopharmaceutical company, from 2009 until the company’s sale in 2012 to Bristol-Myers Squibb Co. Prior to that, she served on the board of directors Abgenix, Inc. (formerly ABGX), a biopharmaceutical company, from 2001 until the company was sold to Amgen, Inc. in 2006. From 1997 to 2005, Dr. Behrens was a director of the Board on Science, Technology and Economic Policy for the National Research Council.

Dr. Behrens was also a Co-Founder of the Coalition for 21st Century Medicine, a trade association for new generation diagnostics companies.

Dr. Behrens holds a B.S. in Biology and a Ph.D. in Microbiology from the University of California, Davis.

Mr. Capper joined MIMEDX in January 2023 to serve as Chief Executive Officer and Director. A highly experienced and accomplished healthcare executive, he brings nearly 30 years of experience in MedTech and Life Sciences leadership roles, along with a track record of substantial value creation.

Mr. Capper has successfully led several organizations, most recently serving as the CEO of BioTelemetry, guiding the company through a significant turn-around, which culminated with its acquisition by Royal Philips for $2.8 billion. Prior to BioTelemetry, he served as President and CEO of both Home Diagnostics and CCS Medical. Mr. Capper brings with him a wealth of commercial experience, having held several leadership roles earlier in his career during the decade he spent with Bayer AG. Additionally, he was an officer in the U.S. Navy serving with distinction as a naval aviator.

Mr. Capper received his undergraduate degree in Accounting from West Chester University and MBA in
International Finance from George Washington University.

Mr. Hawkins serves as a Senior Advisor to EW Healthcare Partners, a life sciences private equity firm. Mr. Hawkins is the former Chairman and CEO of Medtronic, Inc., a global leader in medical technology. He was at Medtronic from 2002 until 2011. After retiring from Medtronic, he served as President and Chief Executive Officer of Immucor, Inc., a private equity backed global leader in transfusion and transplant medicine from October 2011 to July 2015. From 1998 to 2001 Mr. Hawkins served as President and Chief Executive Officer of Novoste Corporation (NASDAQ:NOVST), an interventional cardiology company. 

Prior to that, Mr. Hawkins served in a variety of senior roles at American Home Products, a consumer, pharma and medical device company, Johnson & Johnson, a healthcare company, Guidant Corporation, a medical products company, and Eli Lilly and Company, a global pharmaceutical company. Mr. Hawkins also serves as a director of Biogen Inc. (NASDAQ: BIIB), a biopharmaceutical company; Avanos Medical, Inc. (NYSE:AVNS), a medical technology company; as Chairman of Bioventus, LLC; as Chairman of 4 Tech; and as a director of AskBio, Cirtec, Virtue Labs, Immucor, Inc., Cereius, Inc. and Baebies, Inc., all of which are life science companies. He previously served on the board of Thoratec Corporation. Mr. Hawkins is Vice Chair of the Duke University Board of Trustees and is Chair of the Duke University Health System. Mr. Hawkins was elected as a member of the AIMBE College of Fellows and the National Academy of Engineering. 

He has a dual B.S.E.E. degree in Electrical and Biomedical Engineering from Duke University and a M.B.A. from the University of Virginia’s Darden School of Business. Mr. Hawkins has significant leadership experience as a chief executive officer, significant knowledge of, and experience in, the healthcare industry and significant international experience. He also has extensive governance and public company board experience.

Dr. Laurencin currently serves the Albert and Wilda Van Dusen Distinguished Endowed Professor of Orthopaedic Surgery at the University of Connecticut, and is one of two designated University Professors at the school. He is also a materials scientist and engineer and is Professor of Materials Science and Engineering, Professor of Chemical and Biomolecular Engineering, and Professor of Biomedical Engineering at the University of Connecticut. He has been a professor at the University of Connecticut since 2008. He is the Chief Executive Officer of The Connecticut Convergence Institute for Translation in Regenerative Engineering. Previously, he served as Vice President for Health Affairs at the University of Connecticut Health Center and Dean of the University of Connecticut School of Medicine. From 2003 until 2008, Dr. Laurencin was the Lillian T. Pratt Distinguished Professor and Chair of the Department of Orthopedic Surgery at the University of Virginia. Dr. Laurencin was also designated a University Professor by the President of the University of Virginia. Prior to 2003, Dr. Laurencin held various positions of increasing responsibility at Drexel University, including the Helen I. Moorehead Distinguished Professor of Chemical Engineering, Vice Chairman of the Department of Orthopedic Surgery and Director of Shoulder Surgery, and at MCP-Hahnemann School of Medicine, where he served as Clinical Professor of Orthopedic Surgery and Research Professor of Pharmacology and Physiology. An International Fellow in Biomaterials Science and Engineering, he received the Founders Award from the Society for Biomaterials. He is an elected member of the National Academy of Medicine, the National Academy of Engineering, and the American Academy of Arts and Sciences. Dr. Laurencin is the recipient of the National Medal of Technology and Innovation, our nation’s highest honor for technological achievement. He has over 500 publications and patents.

Dr. Laurencin received his B.S.E. degree in engineering from Princeton University, his Ph.D. in biochemical engineering and biotechnology from the Massachusetts Institute of Technology, and his M.D. from the Harvard Medical School. Dr. Laurencin is NACD Directorship Certified®. He was nominated to serve as a director because of his experience as a practitioner and professor of orthopaedic surgery, as well as his deep technical, research, and clinical experience.

Ms. Olson is currently a Consulting Partner for Trusted Health Advisors. She joined the MIMEDX Board in February 2024, and serves as a board member for two other public companies, Telix Pharmaceuticals and Castle Biosciences, and a privately held growth-stage company, Langham Logistics. Her prior board appointments include Asuragen, BioTelemetry, Little Rapids Corporation, Diaceutics, and ThermoGenesis Corporation.

Ms. Olson previously served as the president of Nuclear & Precision Health Solutions at Cardinal Health, which develops, manufactures, compounds, dispenses and delivers over ten million, time-critical, patient specific doses annually. Prior to Cardinal Health, Ms. Olson was President of NaviMed, a company focused on personalizing medicine through innovative diagnostics. She also worked for Eli Lilly and Company, where she was tasked with leading the effort to formulate the strategy to create and commercialize diagnostics and companion diagnostics. Ms. Olson also worked for Roche Diagnostics for many years, where she attained the position of President and Chief Executive Officer of Roche Diagnostics Corporation.

Ms. Olson received her bachelor’s degree in business from the University of Minnesota and a master’s degree from St. Thomas University in Minnesota.

Ms. Puhy joined the MIMEDX Board in February 2024, and she previously held board positions at Azenta, Abiomed, Eaton Vance, Reebok, Blue Cross Blue Shield of Massachusetts, and Controlled Risk Insurance Company.

Ms. Puhy previously served as executive vice president and chief operating officer for the Dana-Farber Cancer Institute until her retirement in March 2019. Starting in 1994, she served as chief financial officer of Dana-Farber. Prior to Dana-Farber, Ms. Puhy served as executive vice president and chief financial officer of New England Medical Center (now Tufts Medical Center). She was on the adjunct faculty at Harvard School of Public Health for many years.

Ms. Puhy earned her Master of Business Administration from the Wharton School and received a Bachelor of Arts degree from the University of Pennsylvania.